A. Pilotto et al., The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori, ALIM PHARM, 13(5), 1999, pp. 667-673
Background: Resistance of Helicobacter pylori to antibiotics may be a major
reason for treatment failure. Aim: To evaluate the effect of primary H. py
lori resistance to antibiotics on the cure rates of three anti-H. pylori 1-
week triple therapies.
Methods: One hundred and sixteen consecutive patients diagnosed H. pylori-p
ositive by gastric histology, rapid urease test and culture were enrolled.
Activity of tested antibiotics was determined by means of the E-test. Patie
nts were treated for 7 days with: (i) pantoprazole 40 mg o.d. plus amoxycil
lin 1 g b.d. and metronidazole 250 mg q.d.s. (PAM): (ii) pantoprazole 40 mg
o.d. plus clarithromycin 250 mg b.d, and metronidazole 250 mg q.d.s. (PCM)
; or (iii) pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and clarithrom
ycin 250 mg b.d. (PAC). Two months after completion of therapy, endoscopy a
nd gastric biopsies were repeated,
Results: Primary resistance rates to metronidazole, clarithromycin and amox
ycillin were 17.2, 6.9 and 0%, respectively, Overall H. pylori cure rates e
xpressed as intention-to-treat and per protocol analyses were, respectively
, 79% and 86% with PAM, 82% and 89% with PCM, and 85% and 85% with PAC. Sig
nificantly lower cure rates were observed in metronidazole-resistant patien
ts treated with PAM (56% vs. 96%, P = 0.01) or PCM (50% vs. 97%, P = 0.01).
A trend towards lower H. pylori cure rates was observed in clarithromycin-
resistant patients treated with PCM (67% vs. 91%, P = 0.74) or PAC (50% vs.
87%, P = 0.68).
Conclusion: Primary resistance to metronidazole influences the H, pylori cu
re rate of anti-H. pylori proton pump inhibitor-based triple therapies whic
h include this antibiotic. A similar trend exists for primary clarithromyci
n resistance.